Metrics to compare | ETRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipETRAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.3x | −2.7x | −0.2x | |
PEG Ratio | - | −0.09 | 0.00 | |
Price/Book | −2.3x | −1.0x | 2.6x | |
Price / LTM Sales | - | 10.3x | 2.6x | |
Upside (Analyst Target) | 309.4% | 811.1% | 76.9% | |
Fair Value Upside | Unlock | 19.5% | 14.9% | Unlock |
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.